Possible influences on the expression of X chromosome-linked dystrophin abnormalities by heterozygosity for autosomal recessive Fukuyama congenital muscular dystrophy - PubMed (original) (raw)

Case Reports

Possible influences on the expression of X chromosome-linked dystrophin abnormalities by heterozygosity for autosomal recessive Fukuyama congenital muscular dystrophy

A H Beggs et al. Proc Natl Acad Sci U S A. 1992.

Abstract

Abnormalities of dystrophin, a cytoskeletal protein of muscle and nerve, are generally considered specific for Duchenne and Becker muscular dystrophy. However, several patients have recently been identified with dystrophin deficiency who, before dystrophin testing, were considered to have Fukuyama congenital muscular dystrophy (FCMD) on the basis of clinical findings. Epidemiologic data suggest that only 1/3500 males with autosomal recessive FCMD should have abnormal dystrophin. To explain the observation of 3/23 FCMD males with abnormal dystrophin, we propose that dystrophin and the FCMD gene product interact and that the earlier onset and greater severity of these patients' phenotype (relative to Duchenne muscular dystrophy) are due to their being heterozygous for the FCMD mutation in addition to being hemizygous for Duchenne muscular dystrophy, a genotype that is predicted to occur in 1/175,000 Japanese males. This model may help explain the genetic basis for some of the clinical and pathological variability seen among patients with FCMD, and it has potential implications for understanding the inheritance of other autosomal recessive disorders in general. For example, sex ratios for rare autosomal recessive disorders caused by mutations in proteins that interact with X chromosome-linked gene products may display predictable deviation from 1:1.

PubMed Disclaimer

Similar articles

• The role of the dystrophin-glycoprotein complex in the molecular pathogenesis of muscular dystrophies.
  Matsumura K, Ohlendieck K, Ionasescu VV, Tomé FM, Nonaka I, Burghes AH, Mora M, Kaplan JC, Fardeau M, Campbell KP. Matsumura K, et al. Neuromuscul Disord. 1993 Sep-Nov;3(5-6):533-5. doi: 10.1016/0960-8966(93)90110-6. Neuromuscul Disord. 1993. PMID: 8186706 Review.
• A Japanese family with two types of muscular dystrophy: DNA analysis and the dystrophin test.
  Matsumura K, Toda T, Hasegawa T, Kamei M, Imoto N, Shimizu T. Matsumura K, et al. J Child Neurol. 1991 Jul;6(3):251-6. doi: 10.1177/088307389100600309. J Child Neurol. 1991. PMID: 1875028
• Abnormal expression of dystrophin-associated proteins in Fukuyama-type congenital muscular dystrophy.
  Matsumura K, Nonaka I, Campbell KP. Matsumura K, et al. Lancet. 1993 Feb 27;341(8844):521-2. doi: 10.1016/0140-6736(93)90279-p. Lancet. 1993. PMID: 8094772
• A rapid diagnostic method for a retrotransposal insertional mutation into the FCMD gene in Japanese patients with Fukuyama congenital muscular dystrophy.
  Kato R, Kawamura J, Sugawara H, Niikawa N, Matsumoto N. Kato R, et al. Am J Med Genet A. 2004 May 15;127A(1):54-57. doi: 10.1002/ajmg.a.20669. Am J Med Genet A. 2004. PMID: 15103718
• The muscular dystrophies.
  Bushby KM. Bushby KM. Baillieres Clin Neurol. 1994 Aug;3(2):407-30. Baillieres Clin Neurol. 1994. PMID: 7952855 Review.

Cited by

• The genetic basis of hydrocephalus: genes, pathways, mechanisms, and global impact.
  Hale AT, Boudreau H, Devulapalli R, Duy PQ, Atchley TJ, Dewan MC, Goolam M, Fieggen G, Spader HL, Smith AA, Blount JP, Johnston JM, Rocque BG, Rozzelle CJ, Chong Z, Strahle JM, Schiff SJ, Kahle KT. Hale AT, et al. Fluids Barriers CNS. 2024 Mar 4;21(1):24. doi: 10.1186/s12987-024-00513-z. Fluids Barriers CNS. 2024. PMID: 38439105 Free PMC article. Review.
• Duchenne Muscular Dystrophy and Early Onset Hypertrophic Cardiomyopathy associated with Mutations in Dystrophin and Hypertrophic Cardiomyopathy-Associated Genes.
  Aspit L, Arwas N, Krymko H, Etzion Y, Parvari R, Levitas A. Aspit L, et al. J Pediatr Genet. 2020 Nov 19;11(4):304-308. doi: 10.1055/s-0040-1718724. eCollection 2022 Dec. J Pediatr Genet. 2020. PMID: 36267863 Free PMC article.
• From genotype to phenotype: genetics and medical practice in the new millennium.
  Weatherall D. Weatherall D. Philos Trans R Soc Lond B Biol Sci. 1999 Dec 29;354(1392):1995-2010. doi: 10.1098/rstb.1999.0539. Philos Trans R Soc Lond B Biol Sci. 1999. PMID: 10670020 Free PMC article.
• Severe dystrophinopathy in a patient with congenital hypotonia.
  Cordone G, Bado M, Morreale G, Pedemonte M, Minetti C. Cordone G, et al. Childs Nerv Syst. 1996 Aug;12(8):466-9. doi: 10.1007/BF00261626. Childs Nerv Syst. 1996. PMID: 8891365
• Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 3. Differential diagnosis and prognosis.
  Nicholson LV, Johnson MA, Bushby KM, Gardner-Medwin D, Curtis A, Ginjaar IB, den Dunnen JT, Welch JL, Butler TJ, Bakker E, et al. Nicholson LV, et al. J Med Genet. 1993 Sep;30(9):745-51. doi: 10.1136/jmg.30.9.745. J Med Genet. 1993. PMID: 8411069 Free PMC article.

References

1. 1. AMA Arch Neurol Psychiatry. 1956 May;75(5):500-9 - PubMed
2. 1. Am J Hum Genet. 1989 Oct;45(4):498-506 - PubMed
3. 1. J Neurol Sci. 1991 Sep;105(1):79-87 - PubMed
4. 1. Hum Genet. 1990 Nov;86(1):45-8 - PubMed
5. 1. Neuromuscul Disord. 1991;1(1):19-29 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Molecular Biology Databases

  • The Weizmann Institute of Science GeneCards and MalaCards databases